A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression (Cell220)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Joseph Leventhal, Northwestern University
ClinicalTrials.gov Identifier:
NCT00166712
First received: September 9, 2005
Last updated: January 9, 2015
Last verified: January 2015
  Purpose

This is an open label, single-center, randomized phase IV pilot study of steroid and calcineurin inhibitor avoidance in renal transplant recipients. All patients will receive two doses of alemtuzumab to achieve peripheral T-cell depletion. Intravenous glucocorticoids will be administered prior to alemtuzumab administration to limit cytokine release syndrome in association with this monoclonal antibody, and continued for the first two days post-transplant. Thereafter, steroids will not be used for immunosuppression. All transplant recipients will be started on oral immunosuppressive therapy with mycophenolate mofetil (MMF) prior to transplant. Pretransplant, these patients will be randomized to receive, in addition, either tacrolimus (Tac) or sirolimus.

After six months, patients in the tacrolimus arm who do not experience rejection will be randomized to continue on tacrolimus or to be converted to the combination of sirolimus and MMF. Individuals in this arm of the study who do not experience acute rejection, and demonstrate evidence of donor specific hyporesponsiveness at 9 months post-transplant (those staying on Tac + MMF) or 3 months post-conversion (those converted from Tac + MMF to sirolimus + MMF) will be weaned to MMF monotherapy.

Individuals in the sirolimus + MMF arm who do not experience acute rejection and demonstrate evidence of donor specific hyporesponsiveness at 6 months post-transplant will be weaned to MMF monotherapy.


Condition Intervention Phase
Kidney Transplant Failure and Rejection
Drug: Tacrolimus (TAC)
Drug: Sirolimus
Drug: Alemtuzumab
Drug: Mycophenolate mofetil (MMF)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation

Resource links provided by NLM:


Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • The Incidence of Biopsy-proven Acute Allograft Rejection During the First 12 Months of Transplant. [ Time Frame: Within 12 months post kidney transplant ] [ Designated as safety issue: Yes ]
    The incidence of rejection is determined by the proportion of patients experiencing biopsy proven acute allograft rejection during the first 12 months post-transplant.


Secondary Outcome Measures:
  • Severity of Acute Rejection During the First 6 and 12 Months Post-transplant [ Time Frame: Months 6-12 post-transplant ] [ Designated as safety issue: Yes ]
    The diagnosis of rejection will be based on clinical symptoms and signs, laboratory tests, and confirmed by core renal allograft biopsy.

  • Renal Function at 12 Months Post-transplant [ Time Frame: At 12 months post-transplant ] [ Designated as safety issue: Yes ]
    Laboratory tests for renal function include creatinine or iothalamate glomerular filtration rate (GFR).

  • Incidence of Donor Specific Hyporesponsiveness Allowing for the Conversion to Monotherapy [ Time Frame: At 6 & 9 months post-transplant ] [ Designated as safety issue: Yes ]
    The proportion of subjects for both groups determine this measure: 1) Patients in tacrolimus arm who do not experience acute rejection and demonstrate evidence of donor specific hyporesonsiveness at 9 months post-transplant (those staying on TAC+MMF) or 3 months post-convertion (converted from TAC+MMF to Sirolimus+MMF) will be weaned to MMF monotherapy; 2) Those in the sirolimus+MMF arm who do not experience acute rejection and demonstrate evidence of donor specific hyporesponsiveness at 6 months post-transplant will be weaned to MMF monotherapy.

  • Patient and Graft Survival Rates at 6 and 12 Months Post-transplant [ Time Frame: At 6 & 12 months post-transplant ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: April 2005
Estimated Study Completion Date: July 2015
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group 1: Alemtuzumab + TAC + MMF
Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
Drug: Tacrolimus (TAC)
Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
Other Names:
  • Prograf®
  • FK506
Drug: Alemtuzumab
Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
Other Names:
  • Campath®
  • Campath-1H
  • Mabcampath®
Drug: Mycophenolate mofetil (MMF)
MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
Other Name: Cellcept®
Active Comparator: Group 2: Alemtuzumab + Sirolimus + MMF

Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor.

If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil.

Drug: Sirolimus
Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
Other Names:
  • Rapamune®
  • Rapamycin
Drug: Alemtuzumab
Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
Other Names:
  • Campath®
  • Campath-1H
  • Mabcampath®
Drug: Mycophenolate mofetil (MMF)
MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
Other Name: Cellcept®

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who are male or female age 18-65 years
  2. Donor age 18-65 years
  3. Patients who are single-organ recipients (kidney only)
  4. Women who are of childbearing potential must have a negative serum pregnancy test before transplantation and agree to use a medically acceptable method of contraception throughout the treatment period.
  5. Subject (recipient) is able to understand the consent form and give written informed consent

Exclusion Criteria:

  1. Known sensitivity or contraindication to sirolimus, tacrolimus or MMF
  2. Patient with significant or active infection
  3. Patients with a positive lymphocytotoxic crossmatch using donor lymphocytes and recipient serum
  4. Patients with PRA > 20%
  5. Patients who are pregnant or nursing mothers
  6. Patients whose life expectancy is severely limited by diseases other than renal disease
  7. Ongoing active substance abuse, drug or alcohol
  8. Major ongoing psychiatric illness or recent history of noncompliance
  9. Significant cardiovascular disease (e.g.):

    • Significant non-correctable coronary artery disease
    • Ejection fraction below 30%
    • History of recent myocardial infarction
  10. Malignancy within 3 years, excluding non-melanoma skin cancers
  11. Serologic evidence of infection with HIV or HBVsAg positive
  12. Patients with a screening/baseline total white blood cell count < 4,000/mm3; platelet count < 100,000/mm3; triglycerides > 400 mg/dl; total cholesterol > 300 mg/dl
  13. Investigational drug within 30 days prior to transplant surgery
  14. Anti-T cell therapy within 30 days prior to transplant surgery
  15. Patients using Prednisone
  16. Patients who are ABO incompatible
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00166712

Locations
United States, Illinois
Northwestern University/Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Roche Pharma AG
Investigators
Principal Investigator: Joseph R Leventhal, MD, PhD Northwestern University
  More Information

Publications:

Responsible Party: Joseph Leventhal, Associate Professor, Northwestern University
ClinicalTrials.gov Identifier: NCT00166712     History of Changes
Other Study ID Numbers: STU8789 0811-007, CNV0042139
Study First Received: September 9, 2005
Results First Received: November 29, 2012
Last Updated: January 9, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Northwestern University:
Kidney Transplant
Living Donor Kidney Transplant Recipients

Additional relevant MeSH terms:
Alemtuzumab
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on March 26, 2015